Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | hypothetical protein | 0.2067 | 1 | 1 |
Onchocerca volvulus | 0.2067 | 1 | 1 | |
Loa Loa (eye worm) | DOMON domain-containing protein | 0.1434 | 0.4422 | 0.4422 |
Loa Loa (eye worm) | hypothetical protein | 0.2067 | 1 | 1 |
Onchocerca volvulus | 0.1615 | 0.6009 | 0.2846 | |
Mycobacterium ulcerans | transcriptional regulator | 0.1667 | 0.6468 | 0.5 |
Mycobacterium ulcerans | AcrR family transcriptional regulator | 0.1667 | 0.6468 | 0.5 |
Brugia malayi | Muscle positioning protein 4 | 0.1615 | 0.6009 | 0.2846 |
Plasmodium vivax | cysteine repeat modular protein 1, putative | 0.2067 | 1 | 0.5 |
Trypanosoma cruzi | hypothetical protein, conserved | 0.2067 | 1 | 0.5 |
Toxoplasma gondii | kringle domain-containing protein | 0.2067 | 1 | 0.5 |
Mycobacterium ulcerans | TetR family transcriptional regulator | 0.1667 | 0.6468 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.1615 | 0.6009 | 0.6009 |
Leishmania major | hypothetical protein, conserved | 0.2067 | 1 | 0.5 |
Echinococcus multilocularis | tissue type plasminogen activator | 0.2067 | 1 | 0.5 |
Mycobacterium tuberculosis | Transcriptional regulatory repressor protein (TetR-family) EthR | 0.1667 | 0.6468 | 0.5 |
Mycobacterium leprae | Probable transcriptional regulatory repressor protein (TetR-family) EthR | 0.1667 | 0.6468 | 0.5 |
Plasmodium falciparum | cysteine repeat modular protein 1 | 0.2067 | 1 | 0.5 |
Brugia malayi | Kringle domain containing protein | 0.2067 | 1 | 1 |
Echinococcus granulosus | tissue type plasminogen activator | 0.2067 | 1 | 0.5 |
Loa Loa (eye worm) | TK/ROR protein kinase | 0.2067 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.1434 | 0.4422 | 0.4422 |
Schistosoma mansoni | hypothetical protein | 0.1434 | 0.4422 | 0.4048 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.